1st Middle East Lipid Update Conference 2018

The 1st Middle East Lipid Update Conference 2018 is dedicated to the latest advances and best practices in the management of dyslipidemia and cardiovascular risk for the benefit of patients and the entire population.

Topics

• Major causes of dyslipidemia in the population including diet and inheritance
• Raise awareness of Lipids as a major risk factor for cardiovascular disease in the region
• The mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders
• The role of drug therapy in the management of dyslipidemia
• The appropriate use of lipid-altering drugs in special populations
• The side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
• Effective diet and lifestyle strategies for long-term obesity and dyslipidemia management
• Lipid-lowering therapeutic approaches for older adults
• Current guidelines on the management and treatment of patients with dyslipidemia
• Effective diet and lifestyle ( exercise , weight management) strategies for the management of dyslipidemia and cardiovascular risk
• Case studies in lipid management to improve treatment and prevention of cardiovascular disease
• Compose a clinical care for reducing risk of CVD in patients with dyslipidemia
• The management of dyslipidemia in special populations based on gender, culture, and disease variables
• Lipid cases for health professionals seeing patients with complex disorders
• Management strategies for the cardiometabolic risk factors of the metabolic syndrome
• How obesity and adiposopathy contribute to the metabolic syndrome and diabetes mellitus
• Clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
• The side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
• Complex dyslipidemia and dyslipidemia in special populations
• Combination therapies for the management of complex lipid disorders and residual risk

Who should Attend

• Decision Makers
• Public Health Leaders
• Academics
• Scientists
• Healthcare professionals
• Researchers